OBJECTIVE: The objective of the study was to evaluate the effects of dosimetrically guided I-131 prescribed activities on hematopoiesis reflected by changes in complete blood counts (CBCs). DESIGN: This was a retrospective analysis. SETTING: The study was conducted at an academic center. PATIENTS: A total of 152 patients with differentiated thyroid cancer who had 185 dosimetrically guided I-131 treatments. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Repeated-measure ANOVA was used for the analysis of the differences in the averages of CBCs that were documented at baseline and 1, 6, 12, 24–36, and 48–60 months after I-131 treatment. RESULTS: All parameters decreased to their respective nadir at 1 month and then gradually returned toward baseline values. White blood cells (WBCs) and platelets (PLTs) were the most significantly affected cells. At 1 month, the decrease was 29.6% (P < .0001) for WBCs and 25% (P < .0001) for PLTs, whereas at 12 months, the decrease was 15.5% (P < .0001) and 13% (P < .0001), respectively. Lymphocytes appeared to be more susceptible to I-131 than neutrophils (ANCs). The decreases were small in absolute numbers for red blood cells, hematocrit and hemoglobin not surpassing 10%. Multivariate analysis demonstrated that the ratio of administered prescribed activity-to-maximum tolerated activity was associated with the decreases in WBCs (P = .0038), ANCs (P = .0063), and red blood cells (P = .029), with borderline significance for PLTs (P = .057) and hemoglobin (P = .057). CONCLUSIONS: Dosimetrically guided I-131 resulted in statistically significant decreases in CBC parameters, which were more prominent in WBCs and PLTs. Lymphocytes were more severely affected than ANCs, whereas all parameters reached a nadir at 1 month and then gradually returned toward baseline values over the 5-year follow-up of our study.
OBJECTIVE: The objective of the study was to evaluate the effects of dosimetrically guided I-131 prescribed activities on hematopoiesis reflected by changes in complete blood counts (CBCs). DESIGN: This was a retrospective analysis. SETTING: The study was conducted at an academic center. PATIENTS: A total of 152 patients with differentiated thyroid cancer who had 185 dosimetrically guided I-131 treatments. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Repeated-measure ANOVA was used for the analysis of the differences in the averages of CBCs that were documented at baseline and 1, 6, 12, 24–36, and 48–60 months after I-131 treatment. RESULTS: All parameters decreased to their respective nadir at 1 month and then gradually returned toward baseline values. White blood cells (WBCs) and platelets (PLTs) were the most significantly affected cells. At 1 month, the decrease was 29.6% (P < .0001) for WBCs and 25% (P < .0001) for PLTs, whereas at 12 months, the decrease was 15.5% (P < .0001) and 13% (P < .0001), respectively. Lymphocytes appeared to be more susceptible to I-131 than neutrophils (ANCs). The decreases were small in absolute numbers for red blood cells, hematocrit and hemoglobin not surpassing 10%. Multivariate analysis demonstrated that the ratio of administered prescribed activity-to-maximum tolerated activity was associated with the decreases in WBCs (P = .0038), ANCs (P = .0063), and red blood cells (P = .029), with borderline significance for PLTs (P = .057) and hemoglobin (P = .057). CONCLUSIONS: Dosimetrically guided I-131 resulted in statistically significant decreases in CBC parameters, which were more prominent in WBCs and PLTs. Lymphocytes were more severely affected than ANCs, whereas all parameters reached a nadir at 1 month and then gradually returned toward baseline values over the 5-year follow-up of our study.
Authors: Douglas Van Nostrand; Frank Atkins; Fred Yeganeh; Elmo Acio; Randy Bursaw; Leonard Wartofsky Journal: Thyroid Date: 2002-02 Impact factor: 6.568
Authors: B Zachariah; S S Jacob; C Gwede; A Cantor; J Patil; L Casey; A B Zachariah Journal: Int J Radiat Oncol Biol Phys Date: 2001-06-01 Impact factor: 7.038
Authors: Verena Hartung-Knemeyer; James Nagarajah; Walter Jentzen; Marcus Ruhlmann; Lutz S Freudenberg; Alexander R Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme Journal: Ann Nucl Med Date: 2012-07-17 Impact factor: 2.668
Authors: George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-12 Impact factor: 9.236
Authors: Robert Dorn; Juergen Kopp; Harry Vogt; Peter Heidenreich; Robert G Carroll; Seza A Gulec Journal: J Nucl Med Date: 2003-03 Impact factor: 10.057
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Eleonora Molinaro; Rebecca Leboeuf; Brenda Shue; Andrew J Martorella; Martin Fleisher; Steve Larson; R Michael Tuttle Journal: Thyroid Date: 2009-10 Impact factor: 6.568